Safety of a Single Dose of 5 mg of hLF1-11 Given to Autologous Haematopoietic Stem Cell Transplant Recipients
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
The safety and tolerability of hLF 1-11 has to be established first in HSCT recipients who
are at risk of developing, but have not yet developed, infectious complications due to
invasive fungal disease. These patients are different from healthy volunteers because they
have received myeloablative treatment which not only arrests haematopoiesis resulting in
neutropenia but also induces mucosal barrier injury both of which predispose to infections
which typically occur during the week after transplant. It is therefore essential to know
that hLF 1-11 is when given during neutropenia and mucosal barrier injury before infections
ensue